Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities
Identifieur interne : 002A35 ( Main/Exploration ); précédent : 002A34; suivant : 002A36Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities
Auteurs : Warren D. Blackburn Jr. [États-Unis]Source :
- The American Journal of Medicine [ 0002-9343 ] ; 1996.
English descriptors
- Teeft :
- Adhesion, American journal, Antirheumatic drugs, Arthritis, Arthritis rheum, Biopsy, Blackburn, Blood dyscrasias, Clinical trials, Combination therapy, Corticosteroid, Cyclooxygenase inhibition, Cytokine, Disease activity, Disease progression, Dos, Drug therapy, Drug treatment, Erythrocyte sedimentation rate, February, Functional capacity, Higher rate, Inflammatory cells, Inflammatory component, Intercellular adhesion, Liver biopsy, Liver function tests, Liver toxicity, Many years, Medicine volume, Methotrexate, Methotrexate therapy, Monoclonal, Monoclonal antibodies, Monoclonal antibody, Natural hlstory, Nonsteroidal drugs, Nsaid, Nsaid therapy, Oral gold, Outcome measures, Parenteral gold, Pharmacologic therapy, Primary goal, Progression, Pulmonary disease, Pyramid, Radiographic progression, Renal toxicities, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthrlbs, Rheumatoid arthrltls, Rheumatol, Slowacting agents, Tenidap, Therapy, Tissue transplants, Toxicity, Treatment pyramid, Treatment schemes, Treatment strategies, Weight loss.
Abstract
Conventional drug therapy in rheumatoid arthritis (RA) has failed to control the long-term morbidity and mortality associated with RA. Similarly, drug therapy for osteoarthritis (OA) can relieve symptoms, but it is not clear that it alters progression of disease. Three classes of drugs are widely used for treatment of RA: nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and the slow-acting agents. In most patients, pharma cologic therapy is initiated with NSAIDs. These drugs can relieve symptoms but do not alter the course of the disease. The gastrointestinal and other side effects attributed to these compounds are well known. Similarly, use of corticosteroids can provide rapid pain relief to patients with RA and, if used in low doses, pose limited risk of toxicity. Slow-acting agents, including gold, D-penicillamine, and methotrexate, appear to decrease radiographic progression and improve clinical and biochemical indicators of RA. Therefore, newer treatment philosophies encourage use of slow-acting agents earlier in the course of the disease in order to prevent or diminish bone and joint erosions and destruction and other manifestations of disease progression. Drugs under investigation for the treatment of arthritis appear to exhibit disease-modifying or immunomodulating properties. Tenidap is a novel agent that possesses a dual mechanism of action: cyclooxygenase inhibition and modulation of cytokine activity. In addition, several biologic agents, including antibodies to tumor necrosis factor-α (TNF-α) and to intercellular adhesion molecule-1, may prove useful. These immunotherapeutic strategies are based on knowledge of the role of cytokines in the inflammatory process in arthritis. Osteoarthritis may be managed using drug and nondrug modalities. Weight loss is especially important when OA is in the weight-bearing joints. Biopsies of synovium from patients with OA show evidence of inflammation, but whether this disease should be treated with analgesics alone or with anti-inflammatory drugs remains controversial. Other treatment modalities, including tissue transplants and cytokine-modulating drugs, are emerging for the potential therapy of OA. Surgery may also be appropriate if drug treatment fails to control symptoms.
Url:
DOI: 10.1016/S0002-9343(97)89543-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B87
- to stream Istex, to step Curation: 000B87
- to stream Istex, to step Checkpoint: 001825
- to stream Main, to step Merge: 002A87
- to stream Main, to step Curation: 002A35
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities</title>
<author><name sortKey="Blackburn Jr, Warren D" sort="Blackburn Jr, Warren D" uniqKey="Blackburn Jr W" first="Warren D." last="Blackburn Jr.">Warren D. Blackburn Jr.</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:178AF5D02E56C82CBDB57FBE9337255A60791BD6</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1016/S0002-9343(97)89543-5</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-4S9CZCBF-K/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B87</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B87</idno>
<idno type="wicri:Area/Istex/Curation">000B87</idno>
<idno type="wicri:Area/Istex/Checkpoint">001825</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001825</idno>
<idno type="wicri:doubleKey">0002-9343:1996:Blackburn Jr W:management:of:osteoarthritis</idno>
<idno type="wicri:Area/Main/Merge">002A87</idno>
<idno type="wicri:Area/Main/Curation">002A35</idno>
<idno type="wicri:Area/Main/Exploration">002A35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities</title>
<author><name sortKey="Blackburn Jr, Warren D" sort="Blackburn Jr, Warren D" uniqKey="Blackburn Jr W" first="Warren D." last="Blackburn Jr.">Warren D. Blackburn Jr.</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>From the Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea>
<placeName><region type="state">Alabama</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The American Journal of Medicine</title>
<title level="j" type="abbrev">AJM</title>
<idno type="ISSN">0002-9343</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1996">1996</date>
<biblScope unit="volume">100</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="supplement">S1</biblScope>
<biblScope unit="page" from="24S">24S</biblScope>
<biblScope unit="page" to="30S">30S</biblScope>
</imprint>
<idno type="ISSN">0002-9343</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0002-9343</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adhesion</term>
<term>American journal</term>
<term>Antirheumatic drugs</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Biopsy</term>
<term>Blackburn</term>
<term>Blood dyscrasias</term>
<term>Clinical trials</term>
<term>Combination therapy</term>
<term>Corticosteroid</term>
<term>Cyclooxygenase inhibition</term>
<term>Cytokine</term>
<term>Disease activity</term>
<term>Disease progression</term>
<term>Dos</term>
<term>Drug therapy</term>
<term>Drug treatment</term>
<term>Erythrocyte sedimentation rate</term>
<term>February</term>
<term>Functional capacity</term>
<term>Higher rate</term>
<term>Inflammatory cells</term>
<term>Inflammatory component</term>
<term>Intercellular adhesion</term>
<term>Liver biopsy</term>
<term>Liver function tests</term>
<term>Liver toxicity</term>
<term>Many years</term>
<term>Medicine volume</term>
<term>Methotrexate</term>
<term>Methotrexate therapy</term>
<term>Monoclonal</term>
<term>Monoclonal antibodies</term>
<term>Monoclonal antibody</term>
<term>Natural hlstory</term>
<term>Nonsteroidal drugs</term>
<term>Nsaid</term>
<term>Nsaid therapy</term>
<term>Oral gold</term>
<term>Outcome measures</term>
<term>Parenteral gold</term>
<term>Pharmacologic therapy</term>
<term>Primary goal</term>
<term>Progression</term>
<term>Pulmonary disease</term>
<term>Pyramid</term>
<term>Radiographic progression</term>
<term>Renal toxicities</term>
<term>Rheum</term>
<term>Rheumatic diseases</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthrlbs</term>
<term>Rheumatoid arthrltls</term>
<term>Rheumatol</term>
<term>Slowacting agents</term>
<term>Tenidap</term>
<term>Therapy</term>
<term>Tissue transplants</term>
<term>Toxicity</term>
<term>Treatment pyramid</term>
<term>Treatment schemes</term>
<term>Treatment strategies</term>
<term>Weight loss</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Conventional drug therapy in rheumatoid arthritis (RA) has failed to control the long-term morbidity and mortality associated with RA. Similarly, drug therapy for osteoarthritis (OA) can relieve symptoms, but it is not clear that it alters progression of disease. Three classes of drugs are widely used for treatment of RA: nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and the slow-acting agents. In most patients, pharma cologic therapy is initiated with NSAIDs. These drugs can relieve symptoms but do not alter the course of the disease. The gastrointestinal and other side effects attributed to these compounds are well known. Similarly, use of corticosteroids can provide rapid pain relief to patients with RA and, if used in low doses, pose limited risk of toxicity. Slow-acting agents, including gold, D-penicillamine, and methotrexate, appear to decrease radiographic progression and improve clinical and biochemical indicators of RA. Therefore, newer treatment philosophies encourage use of slow-acting agents earlier in the course of the disease in order to prevent or diminish bone and joint erosions and destruction and other manifestations of disease progression. Drugs under investigation for the treatment of arthritis appear to exhibit disease-modifying or immunomodulating properties. Tenidap is a novel agent that possesses a dual mechanism of action: cyclooxygenase inhibition and modulation of cytokine activity. In addition, several biologic agents, including antibodies to tumor necrosis factor-α (TNF-α) and to intercellular adhesion molecule-1, may prove useful. These immunotherapeutic strategies are based on knowledge of the role of cytokines in the inflammatory process in arthritis. Osteoarthritis may be managed using drug and nondrug modalities. Weight loss is especially important when OA is in the weight-bearing joints. Biopsies of synovium from patients with OA show evidence of inflammation, but whether this disease should be treated with analgesics alone or with anti-inflammatory drugs remains controversial. Other treatment modalities, including tissue transplants and cytokine-modulating drugs, are emerging for the potential therapy of OA. Surgery may also be appropriate if drug treatment fails to control symptoms.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Alabama</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Alabama"><name sortKey="Blackburn Jr, Warren D" sort="Blackburn Jr, Warren D" uniqKey="Blackburn Jr W" first="Warren D." last="Blackburn Jr.">Warren D. Blackburn Jr.</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:178AF5D02E56C82CBDB57FBE9337255A60791BD6 |texte= Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities }}
This area was generated with Dilib version V0.6.33. |